Literature DB >> 12862197

Cost-effectiveness analysis: can we reduce variability in costing methods?

Taghreed Adam1, Marc A Koopmanschap, David B Evans.   

Abstract

OBJECTIVES: The need for consistency and standardization of methods for economic appraisals has been recognized for some time and has led to the development of several sets of guidelines for economic evaluations and for costs. Despite this, considerable diversity is still apparent in applied studies. Some of these diversities might be defensible, and some might not. The objectives of this study are to explore sources of variations in the methods used in applied studies and to discuss the nature of these variations and the possibility of reducing some of them.
METHODS: We first use a systematic approach to identify the major sources of variation in costing methods used in applied economic evaluations. We then compare the methods used with the recommendations made in available guidelines.
RESULTS: Four possible sources of variation are identified. The first is where guidelines do not agree in their recommendations; therefore, it is not surprising that applied studies use different methods. The second is where guidelines agree in principle but provide little detail on how to comply with their recommendations; and the third is where a particular methodological issue is not discussed in guidelines. The fourth reason is simply lack of compliance with accepted guidelines.
CONCLUSIONS: Variability in costing methods used in applied studies raises questions about the validity of their results and makes it difficult to compare the results of different studies. We discuss the implications for the transferability and generalizability of results and suggest ways to minimize the variability in the methods so that the results of costing studies and economic evaluations can be of more value to policy-makers.

Mesh:

Year:  2003        PMID: 12862197     DOI: 10.1017/s0266462303000369

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  39 in total

1.  Measuring the time costs of exercise: a proposed measuring method and a pilot study.

Authors:  Lars Axel Hagberg; Lars Lindholm
Journal:  Cost Eff Resour Alloc       Date:  2010-05-11

2.  A decision chart for assessing and improving the transferability of economic evaluation results between countries.

Authors:  Robert Welte; Talitha Feenstra; Hans Jager; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

3.  The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.

Authors:  Andrea Manca; Mark J Sculpher; Ron Goeree
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  The humanistic and economic burden of juvenile idiopathic arthritis in the era of biologic medication.

Authors:  Wendy Gidman; Rachel Meacock; Deborah Symmons
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

5.  Cost accounting in cost utility analysis of screening and treatment.

Authors:  Giedrius Vanagas
Journal:  Br J Ophthalmol       Date:  2005-02       Impact factor: 4.638

6.  Providing systematic guidance in pharmacoeconomic guidelines for analysing costs.

Authors:  Philip Jacobs; Arto Ohinmaa; Bruce Brady
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

7.  Is a methodology available that accurately measures the cost of an FDG-PET study?

Authors:  Bruno Krug; Anne Sophie Pirson; Ralph Crott; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-08       Impact factor: 9.236

8.  Activity-based costing evaluation of [18F]-fludeoxyglucose production.

Authors:  Bruno Krug; Annie Van Zanten; Anne-Sophie Pirson; Ralph Crott; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-21       Impact factor: 9.236

Review 9.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Authors:  Sun-Young Kim; Sue J Goldie
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 10.  Economic evaluation and transferability of physical activity programmes in primary prevention: a systematic review.

Authors:  Silke B Wolfenstetter; Christina M Wenig
Journal:  Int J Environ Res Public Health       Date:  2010-04-09       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.